Jonathan N Townend

List of Publications by Year
in descending order

87	3,791	186265	128289
papers	citations	28 h-index	60 g-index

90	90	90	6356
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Longitudinal Study of Mitral Regurgitation Detected after Acute Myocardial Infarction. Journal of Clinical Medicine, 2022, 11, 965.	2.4	0
2	Risk for subsequent hypertension and cardiovascular disease after living kidney donation: is it clinically relevant?. CKJ: Clinical Kidney Journal, 2022, 15, 644-656.	2.9	3
3	Changing trends in the incidence, management and outcomes of coronary artery perforation over an 11-year period: single-centre experience. Open Heart, 2022, 9, e001916.	2.3	1
4	Sudden cardiac death in chronic renal disease: aetiology and risk reduction strategies. Nephrology Dialysis Transplantation, 2021, 36, 1386-1388.	0.7	7
5	Acute Presentation of Structural Valve Degeneration in a Transcatheter Heart Valve (Sapien XT) at 7.5 Years; Successful Redo TAVR With a Sapien 3 Ultra. CJC Open, 2021, 3, 383-386.	1.5	2
6	Changes in left ventricular structure and function associated with renal transplantation: a systematic review and metaâ€analysis. ESC Heart Failure, 2021, 8, 2045-2057.	3.1	11
7	Improving the diagnosis of heart failure in patients with atrial fibrillation. Heart, 2021, 107, 902-908.	2.9	7
8	Contemporary use of excimer laser in percutaneous coronary intervention with indications, procedural characteristics, complications and outcomes in a university teaching hospital. Open Heart, 2021, 8, e001522.	2.3	0
9	Cardiovascular Effects of Unilateral Nephrectomy in Living Kidney Donors at 5 Years. Hypertension, 2021, 77, 1273-1284.	2.7	8
10	Screening for occult coronary artery disease in potential kidney transplant recipients: time for reappraisal?. CKJ: Clinical Kidney Journal, 2021, 14, 2472-2482.	2.9	3
11	Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, CJN.01930221.	4.5	6
12	Mitral Regurgitation Following Acute Myocardial Infarction Treated by Percutaneous Coronary Interventionâ€"Prevalence, Risk factors, and Predictors of Outcome. American Journal of Cardiology, 2021, 157, 22-32.	1.6	5
13	The characteristics of mitral regurgitation: Data from patients admitted following acute myocardial infarction. Data in Brief, 2021, 39, 107451.	1.0	1
14	Antithrombotic treatment following coronary artery bypass surgery: a network meta-analysis. The Cochrane Library, 2021, 2021, .	2.8	0
15	Defining Myocardial Abnormalities Across the Stages of Chronic Kidney Disease. JACC: Cardiovascular Imaging, 2020, 13, 2357-2367.	5.3	27
16	P0254MYOCARDIAL TISSUE CHARACTERIZATION IN LIVING KIDNEY DONORS 5 YEARS AFTER NEPHRECTOMY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
17	Changes in Blood Pressure and Arterial Hemodynamics following Living Kidney Donation. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1330-1339.	4.5	9
18	Coronary flow velocity reserve and inflammatory markers in living kidney donors. International Journal of Cardiology, 2020, 320, 141-147.	1.7	6

#	Article	IF	Citations
19	Clinical Potential of Targeting Fibroblast Growth Factorâ€23 and Î±Klotho in the Treatment of Uremic Cardiomyopathy. Journal of the American Heart Association, 2020, 9, e016041.	3.7	20
20	Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life. JAMA - Journal of the American Medical Association, 2020, 324, 2497.	7.4	118
21	Coronary microvascular dysfunction: a key step in the development of uraemic cardiomyopathy?. Heart, 2019, 105, 1302-1309.	2.9	24
22	Measuring frailty in patients undergoing TAVI: how and why?. European Heart Journal, 2019, 40, 2240-2242.	2.2	6
23	Early effects of kidney transplantation on the heart - A cardiac magnetic resonance multi-parametric study. International Journal of Cardiology, 2019, 293, 272-277.	1.7	21
24	Comparison of Routine Versus Selective Glycoprotein IIb/IIIa Inhibitors Usage in Primary Percutaneous Coronary Intervention (from the British Cardiovascular Interventional Society). American Journal of Cardiology, 2019, 124, 373-380.	1.6	6
25	72â€...Out-of-hospital cardiac arrest survivors undergoing emergency PCI have an excellent neurological recovery. , 2019, , .		0
26	73â€...Outcomes in patients undergoing percutaneous coronary intervention with chronic kidney disease. , 2019, , .		0
27	What is the cause of hypotension? A rare complication of percutaneous coronary intervention of a chronic total occlusion: a case report. European Heart Journal - Case Reports, 2019, 3, 1-5.	0.6	3
28	Arterial stiffness in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2019, 28, 527-536.	2.0	11
29	Myocardial characterization in pre-dialysis chronic kidney disease: a study of prevalence, patterns and outcomes. BMC Cardiovascular Disorders, 2019, 19, 295.	1.7	7
30	Vive les Differences!â€"A case for optimism in the treatment of patients with heart failure and preserved ejection fraction?. International Journal of Clinical Practice, 2019, 73, e13307.	1.7	0
31	Results of Serial Myocardial Perfusion Imaging in End-Stage Renal Disease. American Journal of Cardiology, 2018, 121, 661-667.	1.6	4
32	24â€...Myocardial tissue characterisation in progressive CKD: is diffuse interstitial fibrosis the key intermediary of uraemic cardiomyopathy?. , 2018, , .		0
33	Chronic kidney disease as a cardiovascular risk factor: lessons from kidney donors. Journal of the American Society of Hypertension, 2018, 12, 497-505.e4.	2.3	13
34	A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial. American Heart Journal, 2017, 191, 37-46.	2.7	10
35	A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. BMJ Open, 2017, 7, e015099.	1.9	37
36	Transcatheter Aortic Valve Implantation With or Without Percutaneous Coronary Artery Revascularization Strategy: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2017, 6, .	3.7	116

#	Article	IF	Citations
37	10â€...Cardiac alterations after renal transplant; contoversies unravelled by cardiac mri. Heart, 2017, 103, A6-A7.	2.9	1
38	11â€...Cpex testing detects subclinical cardiac limitation to exercise in early stage ckd. Heart, 2017, 103, A7.1-A7.	2.9	1
39	MP387CARDIAC LIMITATION OCCURS EARLY IN CKD, AND CANNOT BE FULLY EXPLAINED BY ISCHAEMIA OR REDUCED LV COMPLIANCE AS MEASURED BY DIASTOLIC FUNCTION DURING EXERCISE. Nephrology Dialysis Transplantation, 2017, 32, iii570-iii570.	0.7	0
40	MP392CARDIOPULMONARY EXERCISE TESTING DETECTS SUBCLINICAL CARDIAC LIMITATION TO EXERCISE IN EARLY STAGE CKD. Nephrology Dialysis Transplantation, 2017, 32, iii572-iii572.	0.7	0
41	CKD Associated Cardiomyopathy: Molecular Mechanisms, Imaging Modalities, Disease Evolution and Interventions. , 2017, , 45-58.		1
42	Mechanical effects of left ventricular midwall fibrosis in non-ischemic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2016, 18, 1.	3.3	111
43	SPRINTing towards trials of blood pressure reduction to reduce CKD progression?. European Heart Journal Quality of Care & Clinical Outcomes, 2016, 2, 229-230.	4.0	1
44	Results and lessons from the Spironolactone To Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease (STOP-CKD) randomised controlled trial. BMJ Open, 2016, 6, e010519.	1.9	16
45	Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrology, 2016, 17, 127.	1.8	134
46	Caveolin-1 single-nucleotide polymorphism and arterial stiffness in non-dialysis chronic kidney disease. Nephrology Dialysis Transplantation, 2016, 31, 1140-1144.	0.7	10
47	Cardiovascular Effects of Unilateral Nephrectomy in Living Kidney Donors. Hypertension, 2016, 67, 368-377.	2.7	85
48	Prognostic Utility of Calcium Scoring as an Adjunct to Stress Myocardial Perfusion Scintigraphy in End-Stage Renal Disease. American Journal of Cardiology, 2016, 117, 1387-1396.	1.6	17
49	37â€...Cardiovascular Effects of Unilateral Nephrectomy in Human Kidney Donors. Heart, 2015, 101, A20.2-A21.	2.9	0
50	Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes and Endocrinology,the, 2015, 3, 514-525.	11.4	604
51	Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: A systematic review and meta-analysis of randomized trials. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 599-613.	1.7	17
52	Comparison of magnetic resonance feature tracking for systolic and diastolic strain and strain rate calculation with spatial modulation of magnetization imaging analysis. Journal of Magnetic Resonance Imaging, 2015, 41, 1000-1012.	3.4	87
53	Coronary Artery Calcium Assessment in CKD: Utility in Cardiovascular Disease Risk Assessment and Treatment?. American Journal of Kidney Diseases, 2015, 65, 937-948.	1.9	37
54	Diffuse Interstitial Fibrosis and Myocardial Dysfunction in Early Chronic Kidney Disease. American Journal of Cardiology, 2015, 115, 1311-1317.	1.6	87

#	Article	IF	Citations
55	Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ, The, 2015, 351, h4451.	6.0	247
56	Phosphate: are we squandering a scarce commodity?. Nephrology Dialysis Transplantation, 2015, 30, 163-168.	0.7	7
57	Endothelial Nitric Oxide Synthase Single Nucleotide Polymorphism and Left Ventricular Function in Early Chronic Kidney Disease. PLoS ONE, 2015, 10, e0116160.	2.5	15
58	Quantification of Left Ventricular Interstitial Fibrosis in Asymptomatic Chronic Primary Degenerative Mitral Regurgitation. Circulation: Cardiovascular Imaging, 2014, 7, 946-953.	2.6	92
59	Effect of A Reduction in glomerular filtration rate after NEphrectomy on arterial STiffness and central hemodynamics: Rationale and design of the EARNEST study. American Heart Journal, 2014, 167, 141-149.e2.	2.7	15
60	Defining the Natural History of Uremic Cardiomyopathy in Chronic Kidney Disease. JACC: Cardiovascular Imaging, 2014, 7, 703-714.	5.3	92
61	Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): study protocol for a randomized controlled pilot trial. Trials, 2014, 15, 158.	1.6	9
62	Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trialâ€“a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25Âmg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial. Trials, 2014, 15, 160.	1.6	29
63	The EARNEST Study: Interarm blood pressure differences should also be recorded. American Heart Journal, 2014, 168, e9.	2.7	0
64	Impaired circumferential and longitudinal myocardial deformation in early stage chronic kidney disease: the earliest features of uremic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2013, 15, .	3.3	3
65	Effects of age and chronic kidney disease on regional aortic distensibility: A cardiovascular magnetic resonance study. International Journal of Cardiology, 2013, 168, 4249-4254.	1.7	17
66	Atrial Fibrillation in CKD: Balancing the Risks and Benefits of Anticoagulation. American Journal of Kidney Diseases, 2013, 62, 615-632.	1.9	69
67	Cardiovascular Effects of Sevelamer in Stage 3 CKD. Journal of the American Society of Nephrology: JASN, 2013, 24, 842-852.	6.1	108
68	Arterial disease in chronic kidney disease. Heart, 2013, 99, 365-372.	2.9	119
69	Cytomegalovirus Seropositivity Is Associated with Increased Arterial Stiffness in Patients with Chronic Kidney Disease. PLoS ONE, 2013, 8, e55686.	2.5	33
70	Letter by Moody et al Regarding Article â€œPrevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fractionâ€. Circulation, 2012, 126, e62; author reply e64-5.	1.6	0
71	Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: a cardiac magnetic resonance study. Heart, 2012, 98, 219-224.	2.9	64
72	Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: Cause or association?. Atherosclerosis, 2012, 223, 86-94.	0.8	107

#	Article	IF	Citations
73	Aortic Calcification and Femoral Bone Density Are Independently Associated with Left Ventricular Mass in Patients with Chronic Kidney Disease. PLoS ONE, 2012, 7, e39241.	2.5	10
74	The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. British Journal of Clinical Pharmacology, 2012, 73, 447-454.	2.4	55
75	Serum phosphate but not pulse wave velocity predicts decline in renal function in patients with early chronic kidney disease. Nephrology Dialysis Transplantation, 2011, 26, 2576-2582.	0.7	64
76	Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised controlled trial. Trials, 2011, 12, 30.	1.6	10
77	Does immunosuppressant medication lower blood pressure and arterial stiffness in patients with chronic kidney disease? An observational study. Hypertension Research, 2011, 34, 113-119.	2.7	17
78	Echocardiography in the Potential Heart Donor. Transplantation, 2010, 89, 894-901.	1.0	51
79	Effect of Spironolactone on Left Ventricular Systolic and Diastolic Function in Patients With Early Stage Chronic Kidney Disease. American Journal of Cardiology, 2010, 106, 1505-1511.	1.6	55
80	The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. Clinical Endocrinology, 2010, 73, 566-572.	2.4	19
81	Republished paper: Arterial stiffness in chronic kidney disease: causes and consequences. Postgraduate Medical Journal, 2010, 86, 560-566.	1.8	15
82	Arterial stiffness in chronic kidney disease: causes and consequences. Heart, 2010, 96, 817-823.	2.9	124
83	The haemodynamic effects of adjunctive hormone therapy in potential heart donors: a prospective randomized double-blind factorially designed controlled trial. European Heart Journal, 2009, 30, 1771-1780.	2.2	111
84	Effect of Spironolactone on Left Ventricular Mass and Aortic Stiffness in Early-Stage Chronic Kidney Disease. Journal of the American College of Cardiology, 2009, 54, 505-512.	2.8	256
85	Upregulation of the Nitric Oxide-cGMP Pathway in Aged Myocardium. Circulation Research, 2001, 88, E48.	4.5	1
86	Nitric Oxide and Cardiac Autonomic Control in Humans. Hypertension, 2000, 36, 264-269.	2.7	148
87	Role of nitric oxide in the regulation of cardiovascular autonomic control. Clinical Science, 1999, 97, 5-17.	4.3	128